Pure Global AI
NCT05975905Recruiting

A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS).

A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (TROPOS)
Keros Therapeutics, Inc.Phase 2ClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Pulmonary Arterial Hypertension
Drug/Device/Intervention
Dose A KER-012
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Keros Therapeutics, Inc.
Location
Sydney, Australia
Timeline & enrollment
Phase
Phase 2
Start date
Jun 27, 2023
End date
Jan 31, 2027
Enrollment
90 participants
Primary outcome

Change from Baseline in PVR (Pulmonary Vascular Resistance)

Summary

Study KER-012-A201 is Phase 2, double-blind, randomized, placebo-controlled study to
 determine the efficacy and safety of KER-012 compared to Placebo in adults with PAH (WHO
 Group 1 PH) on stable background PAH therapy. The study is divided into the Screening Period,
 Treatment Period, Extension Period, and Follow-Up Period.

ICD-10 classifications
Primary pulmonary hypertensionOther secondary pulmonary hypertensionPulmonary heart disease and diseases of pulmonary circulationStenosis of pulmonary arteryPulmonary heart disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05975905
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05975905 through Pure Global AI's free database. This Phase 2 trial is sponsored by Keros Therapeutics, Inc. and is currently Recruiting. The study focuses on Pulmonary Arterial Hypertension. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.